1.
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiologica...
by Yusuf, Salim, Prof
The Lancet (British edition), 2011, Vol.378 (9798), p.1231-1243
2.
Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)
by Serruys, Patrick W
The Lancet (British edition), 1998, Vol.352 (9129), p.673-681
3.
Rationale and design of ACTIVE: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events
by Connolly, S
The American heart journal, 2006, Vol.151 (6), p.1187-1193
4.
Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study da...
by Khatib, Rasha, PhD
The Lancet (British edition), 2016, Vol.387 (10013), p.61-69
5.
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
by O'Donoghue, Michelle L, Dr
The Lancet (British edition), 2009, Vol.374 (9694), p.989-997
6.
Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial
by Collet, Jean-Philippe, Prof
The Lancet (British edition), 2014, Vol.384 (9954), p.1577-1585
7.
Acute myocardial infarction
by Reed, Grant W, MD
The Lancet (British edition), 2016, Vol.389 (10065), p.197-210
8.
Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial
by Roberts, Jason D, MD
The Lancet (British edition), 2012, Vol.379 (9827), p.1705-1711
9.
Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study
by Li, Linxin, DPhil
The Lancet (British edition), 2017, Vol.390 (10093), p.490-499
10.
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis
by Mega, Jessica L, Dr
The Lancet (British edition), 2010, Vol.376 (9749), p.1312-1319
11.
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study
by Stone, Gregg W, Dr
The Lancet (British edition), 2013, Vol.382 (9892), p.614-623
12.
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial
by Derdeyn, Colin P, Prof
The Lancet (British edition), 2014, Vol.383 (9914), p.333-341
13.
Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad
by Ahmed, Sakir
Clinical rheumatology, 2020-07-11, Vol.39 (9), p.2529-2543
14.
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLAT...
by Wallentin, Lars, Prof
The Lancet (British edition), 2010, Vol.376 (9749), p.1320-1328
15.
Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials
by Rothwell, Peter M, Prof
The Lancet (British edition), 2016-07-23, Vol.388 (10042), p.365-375
16.
Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)
by Ballantyne, Christie M., MD
The American journal of cardiology, 2012, Vol.110 (7), p.984-992
17.
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial
by Halkes, PHA
The Lancet (British edition), 2006, Vol.367 (9523), p.1665-1673
18.
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised cont...
by Montalescot, Gilles, Prof
The Lancet (British edition), 2009, Vol.373 (9665), p.723-731
19.
20.
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
by Mehran, Roxana, Dr
The Lancet (British edition), 2009, Vol.374 (9696), p.1149-1159
